This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morrison, A J Articles by Wenzel, R P Search for Related Content PubMed PubMed Citation Articles by Morrison, A J, Jr Articles by Wenzel, R P

 Previous Article  |  Next Article 

J Clin Microbiol. 1986 July; 24(1): 52-55

Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

ABSTRACT

We studied the spectrum of clinical disease in 99 patients with nosocomial Pseudomonas maltophilia isolates at the University of Virginia Hospital from 1981 through 1984. The annual rate of isolation increased from 7.1 to 14.1 per 10,000 patient discharges. A crude mortality rate of 43% was documented in all patients from whom the organism was cultured, and the data include 12 patients with nosocomial bacteremia (four deaths). Risk factors associated with death for patients having a P. maltophilia isolate included the following: requirement for care in any intensive care unit during hospitalization (P = 0.0001), patient age over 40 years (P = 0.002), and a pulmonary source for the P. maltophilia isolate (P = 0.003). All P. maltophilia isolates were susceptible to trimethoprim-sulfamethoxazole, 60% of the isolates were resistant to all aminoglycosides (amikacin, tobramycin, and gentamicin), and more than 75% of the isolates were resistant to all beta-lactam antibiotics. The antibiotic susceptibility pattern allows for a niche exploitable in the hospital microbial environment by an organism with a marked associated mortality.

This article has been cited by other articles:

• Falagas, M. E., Valkimadi, P.-E., Huang, Y.-T., Matthaiou, D. K., Hsueh, P.-R. (2008). Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 0: dkn301v1-6 [Abstract] [Full Text]  
• Pathmanathan, A., Waterer, G. W. (2005). Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 25: 911-914 [Abstract] [Full Text]  
• Vidal, F., Mensa, J., Almela, M., Olona, M., Martinez, J.A., Marco, F., Lopez, M.J., Soriano, A., Horcajada, J.P., Gatell, J.M., Richart, C. (2003). Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa. QJM 96: 227-234 [Abstract] [Full Text]  
• Krzewinski, J. W., Nguyen, C. D., Foster, J. M., Burns, J. L. (2001). Use of Random Amplified Polymorphic DNA PCR To Examine Epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from Patients with Cystic Fibrosis. J. Clin. Microbiol. 39: 3597-3602 [Abstract] [Full Text]  
• Visalli, M. A., Jacobs, M. R., Appelbaum, P. C. (1998). Activities of Three Quinolones, Alone and in Combination with Extended-Spectrum Cephalosporins or Gentamicin, against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 42: 2002-2005 [Abstract] [Full Text]  
• Denton, M., Todd, N. J., Kerr, K. G., Hawkey, P. M., Littlewood, J. M. (1998). Molecular Epidemiology of Stenotrophomonas maltophilia Isolated from Clinical Specimens from Patients with Cystic Fibrosis and Associated Environmental Samples. J. Clin. Microbiol. 36: 1953-1958 [Abstract] [Full Text]  
• Denton, M., Kerr, K. G. (1998). Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11: 57-80 [Abstract] [Full Text]  
• Vartivarian, S. E., Papadakis, K. A., Palacios, J. A., Manning, J. T., Anaissie, E. J. (1994). Mucocutaneous and Soft Tissue Infections Caused by Xanthomonas maltophilia: A New Spectrum. ANN INTERN MED 121: 969-973 [Abstract] [Full Text]